DOI:
10.1055/s-00000019
Fortschritte der Neurologie · Psychiatrie
LinksClose Window
References
Lilly E.
Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results.
2012
https://investor.lilly.com/releasedetail.cfm?ReleaseID=703018
We do not assume any responsibility for the contents of the web pages of other providers.